U.S. health officials have approved a new weight-loss pill from Eli Lilly.

For some, GLP-1 drugs feel like a weight-loss miracle. For others, the weight comes right back after they stop taking them, which has led a Jacksonville-area clinical research group to work on finding a solution.

Use of blockbuster anti-obesity drugs like Wegovy and Zepbound is growing, with about 1 in 8 adults in the U.S. saying they currently take the medications.

The biggest new restaurant trend is small.

Publix Pharmacy is now providing savings on select GLP-1 therapies through a new discount card program.

Federal regulators are telling drugmakers to remove label warnings about potential suicidal thoughts and behaviors from their blockbuster weight-loss drugs.

U.S. regulators have approved a pill version of the weight-loss drug Wegovy.

President Donald Trump unveiled a deal Thursday with drugmakers Eli Lilly and Novo Nordisk to expand coverage and reduce prices for their popular obesity treatments Zepbound and Wegovy.

Some of the more than a dozen states that cover the high cost of GLP-1 drugs like Wegovy, Ozempic and Zepbound through Medicaid or state employee insurance programs are scrambling to lessen the budgetary squeeze from fast-rising costs.

Weight loss medications can be beneficial when prescribed for individuals struggling with obesity. However, it’s important to remember that nutrition is still a key part of a healthy weight loss plan.

While West Virginia's employee health insurance program covers drugs like Ozempic for people with type 2 diabetes, officials decided to indefinitely pause covering their use for weight loss patients because of the cost.

The federal government is phasing out off-brand copies of two blockbuster drugs used to treat obesity and diabetes.

Use of diabetes and obesity medications such as Ozempic, Wegovy and other so-called GLP-1 drugs has soared among teens and young adults.